Caribou Biosciences, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Caribou Biosciences, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $17.93M.
- Caribou Biosciences, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $2.22M.
- Caribou Biosciences, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $11.33M, a 1025.12% increase year-over-year.
- Caribou Biosciences, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $134.43M.
- Caribou Biosciences, Inc. stock issued during period, value, new issues for fiscal 2021 was $321.02M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $17.93M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $2.22M 10-Q · filed 2026-08-13 | |
| 2024-03-31 | $11.33M 10-Q · filed 2025-11-12 | |
| 2023-09-30 | $134.43M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $17.29M 10-Q · filed 2023-11-07 | |
| 2023-03-31 | $1.01M 10-Q · filed 2024-08-06 | |
| 2021-12-31 | $321.02M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $321.02M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |